Embed Size (px)
Citation preview
PBL NEWSSeason’s Greetings from PBLSeason’s Greetings from PBL
PBL, Norwich Research Park, Colney Lane, Norwich, Norfolk NR4 7UH, UKTel: +44(0)1603 456500 Fax: +44(0)1603 456552 www.pbltechnology.com
Innovation in life sciences
IP protection
Funds and manages
patent filing and
Builds complementary
technology packages
Markets technology to commercial
users
Concludes and monitors
technology licences
Manages and mentors the formation of
new technology-
based businesses
PB
L N
ews
- Is
sue
25 -
Dec
201
2
Now in its tenth year of operation, PBL's TEC Scheme continues to be an extremely successful route for promoting new plant bioscience innovations to industry. In the past three years alone, PBL has offered through the scheme 25 new innovations from 17
different public research institutions in 8 different countries around the world. These include innovations offered by PBL on behalf of , the technology transfer organisation of the French national agricultural research organisation, INRA. Since January 2010, 37 evaluation licences have been taken by the industry members of the TEC Scheme. Nine of these evaluation
agreements also included options to obtain a commercial licence at a later date. Also over the same period, 15 commercial licences have been signed by PBL for technologies promoted through the TEC Scheme, which remains extremely popular with the plant technology industry.
For details of the PBL TEC Scheme, please click .
INRA Transfert
here
The US Patent Office has issued a further patent to PBL from our RNAi patent estate, the fourth to issue during 2012. US patent no. was granted at the end of October. PBL now holds a portfolio of six issued US patents that represent the key to many
applications in the field of RNAi, covering the methods of using siRNA molecules of 20 to 30 nucleotides to effect gene silencing as well as the siRNA molecules themselves and methods to detect siRNA.
For more information, please click or contact Dr Lars von Borcke ([email protected]).
8,299,235
herePBL Tech ID: 99.190
Grant of further RNAi patents
Successes of PBL TEC Scheme: the figures speak for themselves
In October 2012, PBL and OBP ( ) signed a research and development licence for OBP to use the HT-CPMV system developed by George Lomonossoff and Frank Sainsbury at the John Innes Centre to develop vaccines for use in important animal health applications. Previous tests have already shown the successful vaccination of sheep with a blue tongue virus vaccine. The agreement includes the option to obtain a commercial licence, if the development phase is successful.
Please click the following links for previous news items:
For more information, please contact Dr Lars von Borcke ([email protected]).
Onderstepoort Biological Products SOC Limited
March 2012 January 2011 August 2009
PBL Tech ID: 05.386 & 07.439
- - . CPMV Virus
Plant-made Protein Platform: PBL and OBP enter licence foranimal health applications
In 2010 we announced our technology development partnerships with the nd the (
direction, PBL is delighted to announce taking on our first new technology invented in a Chinese research institution. In October, PBL started marketing a new plant biotechnology innovation from one of the leading Chinese Academy of Sciences institutes, the he new technology has already been well received by the international agricultural biotechnology industry.
Jilin Academy of Agricultural Sciences Institute of Botany, Chinese Academy of Sciences
Institute of Genetics and Developmental Biology
(JAAS) aIB-CAS), under which these partners will make and test transgenic crop plants
containing technologies from PBL's portfolio. In a further new
(IGDB). T
For more information, please contact Dr Jan Chojecki ([email protected]).
PBL in China: PBL to promote new technology from IGDB, Beijing
Triterpene biosynthesis in algae
Anne Osbourn at the John Innes Centre has been awarded a SynBio SPARK Award. The project will test the potential of employing microalgae for triterpene production, by using higher plant enzymes covered by PBL patents, to make and augment triterpene scaffolds. It has the potential to pave the way for a low cost, sustainable approach to producing high-value chemical products used as pharmaceutical scaffolds. Using microalgae as a platform has the potential to dramatically reduce costs for the production of a wide range of triterpenes that are currently prohibitively expensive and in some instances not commercially available at present.
For more information, please contact Dr Lars von Borcke ([email protected]).
PBL NEWSSeason’s Greetings from PBLSeason’s Greetings from PBL
PBL, Norwich Research Park, Colney Lane, Norwich, Norfolk NR4 7UH, UKTel: +44(0)1603 456500 Fax: +44(0)1603 456552 www.pbltechnology.com
Innovation in life sciences
IP protection
Funds and manages
patent filing and
Builds complementary
technology packages
Markets technology to commercial
users
Concludes and monitors
technology licences
Manages and mentors the formation of
new technology-
based businesses
PB
L N
ews
- Is
sue
25 -
Dec
201
2
Innovation in life sciences
Growing portfolio of patents in biocontrol area
PBL has recently achieved the grant of various patents from its biocontrol technologies portfolio. While the first patent for the cis-jasmone technology from Rothamsted Research was granted in 2005 (together with grants in Europe and Canada in the same year), the newly granted US Patent No. 8,221,736 extends the scope of the patent cover. In addition the synergist technology (also from RRes) that supports the cis-jasmone technology will grant in the US in the next few months.
In addition good progress has been made with the jasmonic acid seed treatment technology from Lancaster University. Patents covering the technology have now been granted in the US, Mexico and New Zealand and is shortly also going to be granted in Australia.
The IFR Model Gut group has been awarded c. £0.75m for one of the first BBSRC Super Follow-on Fund Awards, which are larger strategic translational awards intended to add significant value to the commercial development of a technology.
Led by Dr Peter Wilde of IFR and Dr Martin Stocks of PBL, the award will be applied to investigate the degree of correlation between the behaviour of various pharmaceutical dosage forms in the Model Gut's in-vitro stomach (The Dynamic Gastric Model, or DGM) and intestinal models, and their behaviour in-vivo. The intention is to validate the DGM as a tool for the pre-clinical development and formulation of both innovator and generic drugs.
A second output of the award will be to demonstrate the potential value of the DGM for investigating areas of pharmaceutical development that are ethically problematic to pursue in a clinical setting, such as the effects of alcohol abuse on dosage form performance, and the formulation of drugs for paediatric or geriatric use.
The Model Gut group plans to coordinate its work with the OrBiTo project - a major study on in-vitro models of drug performance led by a consortium of major pharmaceutical companies and academic collaborators, under the EU Innovative Medicines Initiative (IMI). The OrBiTo companies will provide clinical data sets, some unpublished, that can be compared with the Model Gut outputs, bringing significant added value to the Super-FOF work programme.
For more information, please contact Dr Martin Stocks ([email protected]).PBL Tech ID: 02.301
www.modelgut.com
IFR and PBL awarded a BBSRC Super-FOF award to validate the Model Gut core technology
The Prostate Cancer Foundation is providing $1m to the Institute of Food Research and UEA to study the protective effects of broccoli consumption against prostate cancer. Prof Richard's Mithen's work at John Innes Centre led to the glucoraphanin-rich Beneforté “superbroccoli” now on sale in stores across and .
Please click for more information on this news, or
UK USA
here contact Dr Jan Chojecki ([email protected]).
Major funding awarded for research on glucoraphanin in broccoli
Professor George Lomonossoff of the John Innes Centre (BBSRC Innovator of the Year 2012) has been awarded a Follow-on Fund grant for c. £150k to further develop the N-Cap RNA Mimic system, an RNA encapsidation technology that protects a diagnostic RNA control fragment from degradation by environmental factors.
An early adopter of the N-Cap RNA Mimics, under license from PBL, has been the Animal Health and Veterinary Laboratories Association (AHVLA), who have successfully incorporated them in their proficiency testing systems and are marketing the materials as internal assay controls, under the brand name Tuff-RNA™.
The BBSRC award will be applied to further refinement of the core technology and testing the robustness of the N-Cap materials to various storage conditions, including lyophilisation.
For more information, please contact Dr Martin Stocks ([email protected]).PBL Tech ID: 04.355
BBSRC Follow-on Fund award to John Innes Centre
